CA Patent

CA2521464C — Irna conjugates

Assigned to Alnylam Pharmaceuticals Inc · Expires 2013-02-05 · 13y expired

What this patent protects

Therapeutic iRNA agents and methods of making and using are enclosed.

USPTO Abstract

Therapeutic iRNA agents and methods of making and using are enclosed.

Drugs covered by this patent

givosiran-sodium (GIVOSIRAN SODIUM)

Patent Metadata

Patent number: CA2521464C
Jurisdiction: CA
Classification: —
Expires: 2013-02-05
Drug substance claim: No
Drug product claim: No
Assignee: Alnylam Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.